# Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion

> **NCT02594761** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 132 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Hercules
- **BIOLOGICAL:** Herceptin EU
- **BIOLOGICAL:** Herceptin US

## Key facts

- **NCT ID:** NCT02594761
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2015-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02594761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02594761, "Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02594761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*